Gena Wang
Stock Analyst at Barclays
(3.61)
# 962
Out of 4,479 analysts
136
Total ratings
45.87%
Success rate
6.01%
Average return
Main Sectors:
Top Industries:
29 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintains: Overweight | $236 → $291 | $243.32 | +19.60% | 4 | Jun 25, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $185 → $226 | $156.75 | +44.18% | 6 | Jun 21, 2024 | |
| SLDB Solid Biosciences | Maintains: Overweight | $21 → $18 | $6.27 | +187.08% | 5 | May 16, 2024 | |
| EDIT Editas Medicine | Maintains: Equal-Weight | $11 → $9 | $4.61 | +95.23% | 6 | May 9, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $80 → $67 | $53.95 | +24.19% | 11 | May 9, 2024 | |
| BEAM Beam Therapeutics | Maintains: Equal-Weight | $42 → $33 | $23.05 | +43.17% | 7 | May 8, 2024 | |
| FDMT 4D Molecular Therapeutics | Initiates: Overweight | $45 | $21.34 | +110.87% | 1 | Apr 15, 2024 | |
| KOD Kodiak Sciences | Maintains: Underweight | $2 → $3 | $2.37 | +26.58% | 7 | Apr 1, 2024 | |
| RGNX REGENXBIO | Maintains: Overweight | $45 → $55 | $11.07 | +396.84% | 5 | Mar 7, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $446 → $472 | $471.25 | +0.16% | 13 | Feb 6, 2024 | |
| LEGN Legend Biotech | Maintains: Overweight | $93 → $94 | $46.02 | +104.26% | 6 | Jan 24, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $125 → $111 | $82.13 | +35.15% | 3 | Nov 2, 2023 | |
| PTCT PTC Therapeutics | Maintains: Equal-Weight | $26 → $25 | $31.17 | -19.79% | 10 | Oct 27, 2023 | |
| SGMO Sangamo Therapeutics | Maintains: Overweight | $11 → $9 | $0.33 | +2,627.27% | 2 | Aug 9, 2023 | |
| NTLA Intellia Therapeutics | Maintains: Overweight | $86 → $90 | $22.47 | +300.53% | 5 | Aug 7, 2023 | |
| VIR Vir Biotechnology | Maintains: Overweight | $59 → $41 | $9.10 | +350.55% | 2 | Jul 21, 2023 | |
| BLUE bluebird bio | Upgrades: Overweight | $7 → $8 | $0.98 | +720.26% | 7 | Jun 1, 2023 | |
| IONS Ionis Pharmaceuticals | Maintains: Equal-Weight | $40 → $37 | $47.11 | -21.46% | 5 | May 4, 2023 | |
| ZYME Zymeworks | Maintains: Equal-Weight | $7 → $9 | $8.61 | +4.53% | 1 | Dec 22, 2022 | |
| ARCT Arcturus Therapeutics Holdings | Upgrades: Equal-Weight | $16 → $25 | $23.66 | +5.66% | 5 | Nov 2, 2022 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Equal-Weight | $12 → $14 | $6.67 | +109.90% | 7 | Aug 5, 2022 | |
| CLLS Cellectis | Maintains: Overweight | $9 → $7 | $1.94 | +261.76% | 1 | May 13, 2022 | |
| MGTX MeiraGTx Holdings | Maintains: Overweight | $32 → $18 | $4.10 | +339.02% | 1 | May 13, 2022 | |
| LOGC ContextLogic | Maintains: Overweight | n/a | $5.53 | - | 1 | Nov 17, 2021 | |
| MRNA Moderna | Maintains: Overweight | n/a | $115.95 | - | 3 | Nov 5, 2021 | |
| AXNX Axonics | Maintains: Overweight | n/a | $67.30 | - | 1 | Aug 6, 2021 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | n/a | $41.12 | - | 5 | Aug 3, 2021 | |
| PBYI Puma Biotechnology | Downgrades: Underweight | n/a | $3.28 | - | 5 | Nov 2, 2018 | |
| ABEO Abeona Therapeutics | Initiates: Buy | n/a | $4.20 | - | 1 | Jan 6, 2017 |
Alnylam Pharmaceuticals
Jun 25, 2024
Maintains: Overweight
Price Target: $236 → $291
Current: $243.32
Upside: +19.60%
Sarepta Therapeutics
Jun 21, 2024
Maintains: Overweight
Price Target: $185 → $226
Current: $156.75
Upside: +44.18%
Solid Biosciences
May 16, 2024
Maintains: Overweight
Price Target: $21 → $18
Current: $6.27
Upside: +187.08%
Editas Medicine
May 9, 2024
Maintains: Equal-Weight
Price Target: $11 → $9
Current: $4.61
Upside: +95.23%
CRISPR Therapeutics AG
May 9, 2024
Maintains: Equal-Weight
Price Target: $80 → $67
Current: $53.95
Upside: +24.19%
Beam Therapeutics
May 8, 2024
Maintains: Equal-Weight
Price Target: $42 → $33
Current: $23.05
Upside: +43.17%
4D Molecular Therapeutics
Apr 15, 2024
Initiates: Overweight
Price Target: $45
Current: $21.34
Upside: +110.87%
Kodiak Sciences
Apr 1, 2024
Maintains: Underweight
Price Target: $2 → $3
Current: $2.37
Upside: +26.58%
REGENXBIO
Mar 7, 2024
Maintains: Overweight
Price Target: $45 → $55
Current: $11.07
Upside: +396.84%
Vertex Pharmaceuticals
Feb 6, 2024
Maintains: Overweight
Price Target: $446 → $472
Current: $471.25
Upside: +0.16%
Legend Biotech
Jan 24, 2024
Maintains: Overweight
Price Target: $93 → $94
Current: $46.02
Upside: +104.26%
BioMarin Pharmaceutical
Nov 2, 2023
Maintains: Overweight
Price Target: $125 → $111
Current: $82.13
Upside: +35.15%
PTC Therapeutics
Oct 27, 2023
Maintains: Equal-Weight
Price Target: $26 → $25
Current: $31.17
Upside: -19.79%
Sangamo Therapeutics
Aug 9, 2023
Maintains: Overweight
Price Target: $11 → $9
Current: $0.33
Upside: +2,627.27%
Intellia Therapeutics
Aug 7, 2023
Maintains: Overweight
Price Target: $86 → $90
Current: $22.47
Upside: +300.53%
Vir Biotechnology
Jul 21, 2023
Maintains: Overweight
Price Target: $59 → $41
Current: $9.10
Upside: +350.55%
bluebird bio
Jun 1, 2023
Upgrades: Overweight
Price Target: $7 → $8
Current: $0.98
Upside: +720.26%
Ionis Pharmaceuticals
May 4, 2023
Maintains: Equal-Weight
Price Target: $40 → $37
Current: $47.11
Upside: -21.46%
Zymeworks
Dec 22, 2022
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $8.61
Upside: +4.53%
Arcturus Therapeutics Holdings
Nov 2, 2022
Upgrades: Equal-Weight
Price Target: $16 → $25
Current: $23.66
Upside: +5.66%
BioCryst Pharmaceuticals
Aug 5, 2022
Maintains: Equal-Weight
Price Target: $12 → $14
Current: $6.67
Upside: +109.90%
Cellectis
May 13, 2022
Maintains: Overweight
Price Target: $9 → $7
Current: $1.94
Upside: +261.76%
MeiraGTx Holdings
May 13, 2022
Maintains: Overweight
Price Target: $32 → $18
Current: $4.10
Upside: +339.02%
ContextLogic
Nov 17, 2021
Maintains: Overweight
Price Target: n/a
Current: $5.53
Upside: -
Moderna
Nov 5, 2021
Maintains: Overweight
Price Target: n/a
Current: $115.95
Upside: -
Axonics
Aug 6, 2021
Maintains: Overweight
Price Target: n/a
Current: $67.30
Upside: -
Ultragenyx Pharmaceutical
Aug 3, 2021
Maintains: Overweight
Price Target: n/a
Current: $41.12
Upside: -
Puma Biotechnology
Nov 2, 2018
Downgrades: Underweight
Price Target: n/a
Current: $3.28
Upside: -
Abeona Therapeutics
Jan 6, 2017
Initiates: Buy
Price Target: n/a
Current: $4.20
Upside: -